The following table sets for the significant proof of principle behind each of Angioblast's lead products:
Technology |
Description |
Lead Product |
Development Status |
Adult stem cells |
"Off-the-shelf, allogeneic adult stem cell therapeutics |
Mesenchymal Precursor Cells ("MPCs") |
Efficacy
animals models of human CHF, Acute MI & Macular Degeneration Completion of autologous MPC Phase Ib human trial for chronic ischemic patients Allogeneic Phase 2 trial for Acute MI Allogeneic Phase 2 trial for CHF Allogeneic Phase 2 trial for Cord Blood Transplantation |
Small Molecule Peptides and Antibodies |
Cytokines and antigen-receptor inhibitors |
Stromal-Derived Factor 1 ("SDF-1") |
Efficacy in animal models of human Acute MI and CHF |
DNAzymes |
RNA silencing targeting genes for blood vessel and heart failure repair |
Plasminogen Activator Inhibitor Type 1 ("PAI-1") |
Efficacy in animal models of human PAD, Acute MI, Restenosis and Cancer |
